Here’s what you need to know:
1. The PROMETHEUS Anser test portfolio measures drug concentrations of various IBD treatments and antidrug antibody levels, to help physicians make individualized treatment decisions.
2. The company’s portfolio already includes monitoring tests for anti-TNF agents, including infliximab, infliximab biosimilars and adalimumab.
3. With PROMETHEUS Anser VDZ, the company can now monitor patients being treated with vedolizumab, an IBD treatment commercialized by Takeda Pharmaceutical under the brand name Entyvio.
More articles on gastroenterology and endoscopy:
FMT proves long-term treatment for colonic bacterial infection: 3 study insights
Are patients with elderly onset IBD at increased risk for cancer? 3 study insights
AGA encourages gastroenterologists to watch 3 key policy areas
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.